Table of Contents- “The point of view of EU regulators “– EU regulatory view on PK/PD in drug development CPMP PK/PD guideline 2000 Regulatory expectations CPMP PK/PD guideline 2000 Regulatory expectations CPMP PK/PD guideline 2000 Regulatory expectations “Normal “ populations/pathogens “Special” populations/pathogens EU activities in the context of antimicrobial resistance EU activities in the context of antimicrobial resistance EU activities in the context of antimicrobial resistance |
Author: Bo Aronsson
Email: webmaster@isap.org Home Page: http://www.isap.org/slides.htm Other information: |